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For the full text of this licence, please go to: http://creativecommons.org/licenses/by-nc-nd/2.5/ The structure of 1 is related to several depsipeptides isolated from marine-derived fungi, such as the exumolides 2 from Scytalidium sp., 3 sansalvamide A 3 from Fusarium sp., 4 and zygosporamide 4 from Zygosporium masonii., 5 and was confirmed using a mixture of 1 H / 13 C NMR, degradation and Mosher's ester derivitization studies. This showed that the depsipeptide contained 4 amino acid residues (two L-Pro and two D-Phe) and one hydroxy acid residue (L-Hiv) linked by 4 amide and 1 ester linkage. While all these peptides possess hydrophobic amino acid residues, the presence of the D-Phe residue in 1 is unusual since the only other depsipeptide in this group to have D-amino acid residues is zygosporamide 4 (Figure 1 ). Additionally, the importance of a D-amino acid in analogues of sansalvamide A, in relation to anticancer activity, has been determined by McGuire and McAlpine via SAR studies. [6] [7] [8] [9] [10] Total syntheses of 3 11 and 4 12 have been described previously, however the total synthesis of 1 has yet to be reported. Therefore, in this letter, we would like to report a short, efficient, solution phase total synthesis of 1, confirmation of its reported structure and a single crystal X-ray analysis.
The retrosynthesis of 1 is shown in Scheme 1. Alternaramide 1 can be obtained via either a macrolactonization or a macrolactamization event on the precursor linear peptides 5 and 6, respectively. While there are examples of the use macrolactonization in the synthesis of depsipeptides, [13] [14] [15] [16] such a cyclisation performed on 5 may be problematic. However, due to the short synthetic sequence to give the precursor 5 we thought this would be a viable route to explore, alongside the macrolactamization approach. The synthesis of both precursor linear peptides 5 and 6 would be from the key tetrapeptide 7 using standard peptide coupling protocols. The tetrapeptide 7 would be obtained from L-Pro, D-Phe, and L-Hiv, which can be obtained from L-Val via hydrolytic diazotization. Coupling of proline methyl ester 8 with HO(D)PheHNBoc 9 was initially performed using two coupling methods, either EDC or formation of the mixed anhydride which gave the diamino acid 12 in a good yield of 87% and 86%, respectively (Scheme 2). PyBOP ® was also employed but yields using this coupling reagent were moderate to poor. The TBS protected α-hydroxy acid 13 was obtained in 3steps in 65% yield via the hydrolytic diazotization of L-Val 10 followed by TBS protection. 17 Template for SYNLETT and SYNTHESIS © Thieme Stuttgart · New York 2014-01-07 page 2 of 5 The key tetrapeptide 7 was obtained in 2-steps from 12, by Boc deprotection of 12 with 4M HCl in 1,4-dioxine to give 14, and the hydrolysis of 12 to the free acid using LiOH to give 15, both of which were used without further purification. The salt 14 and free acid 15 were then coupled under EDC conditions to give the key tetra-aminoacid 7 in 52% yield over the 2-steps (Scheme 3). Subsequently, 7 was Boc deprotected and the resultant salt 16 then coupled with the 13 using PyBOP ® giving 17 in a good yield of 71% over 2-steps. The free alcohol and acid on 17 were then sequentially revealed by deprotection using TBAF and followed by treatment with excess aqueous LiOH. Attempted final ring closure of 5 was then trialed with a number of coupling reagents including PyBOP ® , DCC, EDC and 1,3,5-trichlorobenzoyl chloride. 18 The only successful conditions were using excess PyBOP ® and diisopropylethylamine which provided alternaramide 1 in a poor isolated yield of only 5% over the 3-steps, presumably due to the low nucleophilicity of the hydroxyl group. Consequently, route B (Scheme 1) with the final ring closure via a macrolactamization was pursued.
The requisite substrate for the macrolactamization was synthesized in 4-steps from the key tetrapeptide 7 (Scheme 4). A protecting group switch on the L-Hiv fragment was achieved in 2-steps to give the benzyl ester protected L-Hiv fragment 19 in 52% yield. This was then successfully coupled to the saponified tetrapeptide 20 in 73% yield over the 2-steps. Finally, the free acid and amine on 20 were revealed by sequential hydrogenolysis followed by acid mediated Boc deprotection. The macrolactamization of 6 was then achieved using excess PyBOP ® with diisopropyl amine and catalytic DMAP, giving alternaramide 1 in 48% yield over the 3-steps. 19 The spectroscopic data for our synthetic alternaramide sample agreed well with that reported by Oh and coworkers and copies of the relevant 1 H and 13 C NMR spectra are contained within the supplementary information. 20, 21 Crystals suitable for single crystal X-ray analysis were obtained and Figure 2 shows the molecular depiction of one of three similar molecules of (-)-1 in the asymmetric unit. 22 Despite the use of Mo-Kα radiation for this light atom structure, determination of the absolute structure parameter 23 via Parson's Q-value method 24 led to a value that supported the proposed absolute structure for the molecule. The molecular conformation is stabilised by trans-annular hydrogen bonds. In conclusion, we have reported the first total synthesis of alternaramide (-)-1 using standard solution phase peptide coupling protocols. Two synthetic pathways have been investigated using a macrolactonization and a macrolactamization approach giving alternaramide in a best overall yield of 11% in 8-steps. Finally, the structure of synthetic alternaramide (-)-1 was confirmed by single crystal X-ray analysis.
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Supporting Information for this article includes the 1 H and 13 C NMR spectra of synthetic alternaramide (-)-1 and crystallographic data for (-)-1.
